Business 3 min read By Arthur Ellington
Savara resubmits drug application as investors await FDA decision
Savara is awaiting a US Food and Drug Administration decision on its resubmitted application for molgramostim, an inhaled therapy for a rare lung disease, with a quarterly earnings report due shortly before the ruling.
Savara, a biopharmaceutical company, is awaiting a decision from the US Food and Drug Administration on its resubmitted Biologics License Application for molgramostim, an inhaled therapy under development for autoimmune pulmonary alveolar proteinosis. Investors are watching closely, since the ruling is widely seen as the most important near-term catalyst for the company and its share price.
The drug is aimed at autoimmune pulmonary alveolar proteinosis, or aPAP, a rare lung disease in which a substance called surfactant builds up in the air sacs and makes breathing progressively harder. Savara has so far been unable to bring a product to market, and it has no approved products generating revenue. That leaves the company dependent on its regulatory progress and its ability to fund operations until it can start earning income.
The company's earlier application was rejected by the FDA. Savara then resubmitted it after addressing the regulator's concerns. The outcome of the new review remains uncertain, and analysts and investors have not been able to predict it with confidence. An approval would allow the company to move toward commercial launch, while a rejection would represent a significant setback.
Savara's upcoming quarterly earnings report is expected shortly before the FDA decision. Investors are focusing on two issues in particular: the company's cash position and its runway, meaning how long its available funds will last given the expected timeline for approval. The company is not generating revenue, so those figures are central to judging how much room it has if the review takes longer than expected or if it must raise additional capital.
The company's share price has been volatile around regulatory news, and investors are bracing for possible large swings in either direction. A favourable decision could lift the shares sharply, while a rejection could push them down just as quickly. Such moves are common among small biopharmaceutical firms whose valuations depend heavily on a single product's prospects.
Several questions will remain open even after the FDA rules. If the drug is approved, the timing of its commercial launch will determine when revenue can begin. The size of the eventual market is also uncertain, as a therapy for a rare disease serves a limited patient population, which shapes both sales potential and the economics of the business. Until the FDA issues its decision and Savara reports its financial position, those factors will remain unresolved.
Source: investing.com
3
